Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
We believe development-stage biopharmaceutical company MannKind (NASDAQ:MNKD) is a firm with great prospects, and at current levels we think this stock is drastically undervalued.
Over the long term we think MannKind is a decuple, maybe more. Let's have Alfred Mann help us understand why (all quotes are from Alfred Mann on the conference call unless otherwise noted):
1) AFREZZA Is So Very Nice
A lot rides on MannKind's flagship product AFREZZA, its late stage insulin inhalation system that should come up for FDA approval next year.
With the obesity epidemic giving way to a diabetes epidemic, MannKind is moving into the right market at the right time. Currently the global market for diabetes management is upward of $50 billion annually and will surpass $100 billion in the next few years.
If a company can bring a superior way to deliver insulin to market then they'd take a huge chunk of that $100 billion.
http://seekingalpha.com/article/799311-3-reasons-this-speculative-bio-pharma-is-a-winner
Over the long term we think MannKind is a decuple, maybe more. Let's have Alfred Mann help us understand why (all quotes are from Alfred Mann on the conference call unless otherwise noted):
1) AFREZZA Is So Very Nice
A lot rides on MannKind's flagship product AFREZZA, its late stage insulin inhalation system that should come up for FDA approval next year.
With the obesity epidemic giving way to a diabetes epidemic, MannKind is moving into the right market at the right time. Currently the global market for diabetes management is upward of $50 billion annually and will surpass $100 billion in the next few years.
If a company can bring a superior way to deliver insulin to market then they'd take a huge chunk of that $100 billion.
http://seekingalpha.com/article/799311-3-reasons-this-speculative-bio-pharma-is-a-winner